AUROPHARMA:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 923.80


0.00 (0.00)%

Market Cap

INR 543.14B



Average Target Price

INR 988.17 (+6.97%)
Average Analyst Rating


Fundamental Analysis



Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter drugs, and dietary supplements, as well as active pharmaceutical ingredients and finished dosage forms for central nervous system, cardiovascular, anti-retroviral, anti-diabetics, anti-allergies, gastroenterology, antibiotics, dermatology, respiratory, and oncology, as well as specialty generic formulations. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, transdermal patches, inhalers, vaccines, and depot injections. The company also exports its products to approximately 155 countries. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine UB-612 for India and UNICEF. Aurobindo Pharma Limited was founded in 1986 and is headquartered in Hyderabad, India. Address: Water Mark Building, Hyderabad, India, 500084

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2021-01-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..


INR1,380.81B 93.56 35.28
DIVISLAB:NSE Divi's Laboratories Limited


INR938.75B 53.37 39.67
DRREDDY:NSE Dr. Reddy's Laboratories Limit..


INR835.32B 54.50 25.69
LUPIN:NSE Lupin Limited


INR490.77B 49.28 19.69
CADILAHC:NSE Cadila Healthcare Limited


INR472.66B 27.92 17.29
ALKEM:NSE Alkem Laboratories Limited


INR363.48B 24.81 17.31
IPCALAB:NSE Ipca Laboratories Limited


INR259.83B 26.00 17.52
LAURUSLABS:NSE Laurus Labs Limited


INR198.86B 33.20 20.19
APLLTD:NSE Alembic Pharmaceuticals Limite..


INR185.48B 15.69 13.34


INR164.60B 31.47 19.83


Symbol Name Weight Mer Price(Change) Market Cap


Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain -0.43% 60% D- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.43% 60% D- 54% F
Trailing 12 Months  
Capital Gain 84.35% 66% D 86% B
Dividend Return 0.50% 62% D- 35% F
Total Return 84.85% 66% D 86% B
Trailing 5 Years  
Capital Gain 12.80% 41% F 54% F
Dividend Return 1.54% 32% F 15% F
Total Return 14.35% 43% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 3.27% 35% F 56% F
Dividend Return 0.36% 38% F 27% F
Total Return 3.64% 35% F 55% F
Risk Return Profile  
Volatility (Standard Deviation) 33.08% 71% C- 61% D-
Risk Adjusted Return 10.99% 40% F 55% F
Market Capitalization 543.14B 95% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.29 72% C- 56% F
Price/Book Ratio 2.96 57% F 27% F
Price / Cash Flow Ratio 12.40 63% D 31% F
EV/EBITDA 10.42 69% D+ 57% F
Management Effectiveness  
Return on Equity 18.73% 65% D 87% B+
Return on Invested Capital 13.92% 70% C- 82% B-
Return on Assets 9.28% 72% C- 91% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.80 57% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector